Journal article icon

Journal article

20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years

Abstract:
Background The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)–positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment. Methods In this ... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1056/NEJMoa1701830

Authors


More by this author
Department:
Oxford, MSD, Nuffield Department of Population Health, Clinical Trial Service Unit
Role:
Author
More by this author
Department:
Oxford, MSD, Nuffield Department of Population Health, Clinical Trial Service Unit
Role:
Author
More by this author
Department:
Oxford, MSD, Nuffield Department of Population Health, Clinical Trial Service Unit
Role:
Author
More by this author
Department:
Oxford, MSD, Nuffield Department of Population Health, Clinical Trial Service Unit
Role:
Author
More by this author
Department:
Oxford, MSD, Nuffield Department of Population Health, Clinical Trial Service Unit
Role:
Author
Expand authors...
Publisher:
Massachusetts Medical Society Publisher's website
Journal:
New England Journal of Medicine Journal website
Volume:
377
Issue:
19
Pages:
1836-1846
Publication date:
2017-11-09
Acceptance date:
2017-05-23
DOI:
EISSN:
1533-4406
ISSN:
0028-4793
Pubs id:
pubs:702109
URN:
uri:a3cdddf3-1355-43a6-a773-4b15d3b43700
UUID:
uuid:a3cdddf3-1355-43a6-a773-4b15d3b43700
Local pid:
pubs:702109
Paper number:
19

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP